Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab Plus Standard of Care Versus Placebo Plus Standard of Care in Adult Subjects With Active Lupus Nephritis
NCT01639339 is registered in ClinicalTrials.gov with Human Genome Sciences Inc., a GSK Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab Plus Standard of Care Versus Placebo Plus Standard of Care in Adult Subjects With Active Lupus Nephritis
- Lead sponsor
- Human Genome Sciences Inc., a GSK Company
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 12, 2012
- Completion date
- March 12, 2020
- Enrollment
- 448 (actual)
- Sites
- 118
Conditions
As the registry lists them; a condition with its own page is linked.